BioInvent International AB (publ) BOVNF Stock
BioInvent International AB (publ) Price Chart
BioInvent International AB (publ) BOVNF Financial and Trading Overview
| BioInvent International AB (publ) stock price | 3.29 USD |
| Previous Close | 3.29 USD |
| Open | 4.7 USD |
| Bid | 2.84 USD x 10000 |
| Ask | 3.84 USD x 10000 |
| Day's Range | 4.7 - 4.7 USD |
| 52 Week Range | 3.29 - 4.7 USD |
| Volume | 908 USD |
| Avg. Volume | 0 USD |
| Market Cap | 436.28M USD |
| Beta (5Y Monthly) | -0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BOVNF Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6387899 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
BioInvent International AB (publ) Stock Price History
| Beta (5Y Monthly) | -0.05 |
| 52-Week Change | -30.029% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 4.7 USD |
| 52 Week Low | 3.29 USD |
| 50-Day Moving Average | 3.29 USD |
| 200-Day Moving Average | 3.29 USD |
BOVNF Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 65.8M |
| Float | 31.44M |
| Short Ratio | N/A |
| % Held by Insiders | 10.16% |
| % Held by Institutions | 57.11% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -153.97% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 100.00% |
| EBITDA Margin | -155.52% |
Management Effectiveness
| Return on Assets (ttm) | -31.32% |
| Return on Equity (ttm) | -55.50% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | -39.20% |
| Gross Profit (ttm) | N/A |
| EBITDA | -338822016 USD |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.47 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 1.42 USD |
| Current Ratio (mrq) | 5.316 |
| Book Value Per Share (mrq) | 10.379 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | -160400752 USD |
Profile of BioInvent International AB (publ)
| Country | United States |
| State | N/A |
| City | Lund |
| Address | The Gamma Building |
| ZIP | 223 70 |
| Phone | 46 4 62 86 85 50 |
| Website | https://www.bioinvent.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 112 |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin's lymphoma, as well as Phase 1/2a trial to treat solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies.; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Q&A For BioInvent International AB (publ) Stock
What is a current BOVNF stock price?
BioInvent International AB (publ) BOVNF stock price today per share is 3.29 USD.
How to purchase BioInvent International AB (publ) stock?
You can buy BOVNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioInvent International AB (publ)?
The stock symbol or ticker of BioInvent International AB (publ) is BOVNF.
Which industry does the BioInvent International AB (publ) company belong to?
The BioInvent International AB (publ) industry is Biotechnology.
How many shares does BioInvent International AB (publ) have in circulation?
The max supply of BioInvent International AB (publ) shares is 65.8M.
What is BioInvent International AB (publ) Price to Earnings Ratio (PE Ratio)?
BioInvent International AB (publ) PE Ratio is now.
What was BioInvent International AB (publ) earnings per share over the trailing 12 months (TTM)?
BioInvent International AB (publ) EPS is -0.47 USD over the trailing 12 months.
Which sector does the BioInvent International AB (publ) company belong to?
The BioInvent International AB (publ) sector is Healthcare.